A comprehensive view of Upsher-Smith Laboratories Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Upsher-Smith to preview expanding collection of drugs backed by the Promise of Support Program at 2024 AAN Annual Meeting in Denver; drugs include VIGADRONE and TORPENZ, set to be accessible by mid-2024
Published: April 12, 2024 by Upsher-Smith Laboratories Inc.
Bora Pharmaceuticals completes acquisition of Minnesota-based generics manufacturer Upsher-Smith, marking its first manufacturing site in the US; the deal supports Bora’s US manufacturing organization strategies
Published: April 02, 2024 by Upsher-Smith Laboratories Inc.
Upsher-Smith Laboratories launches Methimazole tablets, USP, 5 mg and 10 mg., in the US with potential market value of US$36.8M; original reference is Pfizer's brand Tapazole
Published: April 01, 2024 by M2 Pharma
Taiwan-based Bora Pharmaceuticals to acquire generic drug producer Upsher-Smith Laboratories for up to US$210.0M
Published: March 05, 2024 by BioSpectrum (CBNB Abstracts)
Taiwan-based Bora Pharmaceuticals to acquire US generics maker Upsher-Smith for US$210.0M; deal establishes Bora's first US facility for its CDMO business and strengthens the position of its commercial pharma company TWi in the US market
Published: January 17, 2024 by Contify Life Science News

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count